View Older Stories View More Recent Stories

Aug 21, 2018 07:00AM Alnylam Completes Enrollment in ENVISION Phase 3 Study of Givosiran, an Investigational RNAi Therapeutic for the Treatment of Acute Hepatic Porphyrias (AHPs)
Aug 10, 2018 02:45PM Alnylam Pharma (ALNY) Announces Alignment on Value-Based Agreements with Leading Health Insurers, Launches Comprehensive Patient Support Services for ONPATTRO
Aug 10, 2018 02:37PM Alnylam Announces Alignment on Value-Based Agreements with Leading Health Insurers and Launches Comprehensive Patient Support Services for ONPATTRO™ (patisiran)
Aug 10, 2018 02:30PM Alnylam Pharma (ALNY) Confirms FDA Approval of ONPATTRO for Treatment of Polyneuropathy of hATTR Amyloidosis in Adults
Aug 10, 2018 02:28PM Alnylam Announces First-Ever FDA Approval of an RNAi Therapeutic, ONPATTRO™ (patisiran) for the Treatment of the Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis in Adults
Aug 2, 2018 08:00AM Alnylam Pharmaceuticals Reports Second Quarter 2018 Financial Results and Highlights Recent Period Activity
Jul 27, 2018 09:27AM Alnylam to Webcast Conference Call Discussing Second Quarter 2018 Financial Results
Jul 27, 2018 07:15AM Alnylam Pharma (ALNY) Reports Positive CHMP Opinion for ONPATTRO (patisiran)
Jul 27, 2018 07:15AM Alnylam Receives Positive CHMP Opinion for ONPATTRO™ (patisiran) for the Treatment of Hereditary Transthyretin-Mediated Amyloidosis in Adults with Stage 1 or Stage 2 Polyneuropathy
Jul 23, 2018 07:10AM Alnylam Pharma (ALNY) Highlights New Analyses of Clinical Results from APOLLO Phase 3 Study of Patisiran
Jul 23, 2018 07:00AM Alnylam Presents New Analyses of Clinical Results from APOLLO Phase 3 Study of Patisiran at 2018 Peripheral Nerve Society Annual Meeting
Jul 5, 2018 06:06AM Alnylam Pharma (ALNY) Reports Publication of APOLLO Phase 3 Clinical Study Results for Investigational RNAi Therapeutic Patisiran
Jul 4, 2018 05:10PM Alnylam Announces Publication of APOLLO Phase 3 Clinical Study Results for Investigational RNAi Therapeutic Patisiran in The New England Journal of Medicine
Jun 21, 2018 07:00AM Alnylam to Host Fifth Annual “RNAi Roundtable” Webcast Series
Jun 20, 2018 07:00AM Alnylam Expands Senior Leadership Team with Two Key Appointments
Jun 15, 2018 07:00AM Alnylam to Report New Clinical Results for Patisiran at the 4th Congress of the European Academy of Neurology
Jun 12, 2018 08:00AM Over 700 Alnylam Employees Volunteer at the Company’s 4th Annual “Helping Hands” Community Service Day
Jun 8, 2018 07:02AM Alnylam Pharma (ALNY) Reports Updated Results from Phase 1/2 Study of Lumasiran in Patients with PH1
Jun 8, 2018 07:00AM Alnylam Reports Updated Positive Results from Phase 1/2 Study of Lumasiran in Patients with Primary Hyperoxaluria Type 1 (PH1)
Jun 4, 2018 07:07AM Alnylam Pharma (ALNY) Granted Orphan Drug Designation from FDA for ALN-TTRsc02
Jun 4, 2018 07:00AM Alnylam Receives Orphan Drug Designation from the United States Food & Drug Administration for ALN-TTRsc02, a Subcutaneously Delivered Investigational RNAi Therapeutic for the Treatment of Transth
May 29, 2018 07:00AM Alnylam to Webcast Presentations at Upcoming June Investor Conferences
May 15, 2018 07:09AM Alnylam Pharma (ALNY) Names Colleen Reitan to Board
May 15, 2018 07:00AM Alnylam Appoints Colleen Reitan to the Board of Directors
May 8, 2018 07:00AM Alnylam Reports Preclinical Data Demonstrating Central Nervous System (CNS) Delivery of RNAi Therapeutics
May 3, 2018 04:00PM Alnylam Pharmaceuticals Reports First Quarter 2018 Financial Results and Highlights Recent Period Activity
May 3, 2018 07:41AM Alnylam Pharma (ALNY) Announces Alignment with FDA on Accelerated Development Path for Lumasiran for Primary Hyperoxaluria Type 1
May 3, 2018 07:00AM Alnylam Achieves Alignment with FDA on Accelerated Development Path for Lumasiran, an Investigational RNAi Therapeutic for the Treatment of Primary Hyperoxaluria Type 1 (PH1)
May 1, 2018 04:00PM Alnylam to Webcast Presentations at Upcoming May Investor Conferences
Apr 26, 2018 04:00PM Alnylam to Webcast Conference Call Discussing First Quarter 2018 Financial Results
Apr 24, 2018 07:00AM Alnylam Reports New Clinical Results from the APOLLO Phase 3 Study of Patisiran at the American Academy of Neurology 2018 Annual Meeting
Apr 23, 2018 07:05AM Alnylam Pharma (ALNY) Receives Positive Opinion for Orphan Drug Designation in EU for ALN-TTRsc02
Apr 23, 2018 07:00AM Alnylam Receives Positive Opinion for Orphan Drug Designation in the European Union for ALN-TTRsc02, a Subcutaneously Delivered Investigational RNAi Therapeutic for the Treatment of Transthyretin-Medi
Apr 20, 2018 12:42PM Alnylam Reaches Settlement Agreement with Dicerna Pharmaceuticals Resolving Trade Secret Misappropriation and Other Pending Litigation
Apr 16, 2018 05:42AM Alnylam Pharma (ALNY) Announces New Positive Clinical Results for Givosiran
Apr 14, 2018 01:00AM Alnylam Presents New Positive Clinical Results for Givosiran, an Investigational RNAi Therapeutic for the Treatment of Acute Hepatic Porphyrias
Mar 28, 2018 04:00PM Alnylam and Collaborators to Present Clinical Study Results in Acute Hepatic Porphyrias (AHPs) at The 53rd International Liver Congress™ of the European Association for the Study of the Liver (EASL)
Mar 28, 2018 07:07AM Alnylam Pharma (ALNY) Announces New Clinical Results from the APOLLO Phase 3 Study of Patisiran
Mar 28, 2018 07:00AM Alnylam Presents New Clinical Results from the APOLLO Phase 3 Study of Patisiran at the 16th International Symposium on Amyloidosis
Mar 26, 2018 07:01AM Alnylam Pharma (ALNY) Receives EMA PRIME Designation for Accelerated Assessment of Lumasiran
Mar 26, 2018 07:00AM Alnylam Receives European Medicines Agency PRIME Designation for Accelerated Assessment of Lumasiran, an Investigational RNAi Therapeutic for the Treatment of Primary Hyperoxaluria Type 1 (PH1)
Mar 21, 2018 05:07PM Regeneron (REGN) and Alnylam (ALNY) Announce Pact to Discover New Treatments for NASH
Mar 21, 2018 05:06PM Regeneron and Alnylam Pharmaceuticals Announce Collaboration to Discover New Treatments for Nonalcoholic Steatohepatitis (NASH)
Mar 21, 2018 08:00AM Alnylam to Webcast Presentation at 17th Annual Needham Healthcare Conference
Mar 14, 2018 07:00AM Alnylam to Report New Clinical Results from the APOLLO Phase 3 Study of Patisiran at the 16th International Symposium on Amyloidosis
Mar 13, 2018 08:00AM Alnylam Unveils Resources to ‘Bridge the Gap’ in Knowledge of Hereditary ATTR (hATTR) Amyloidosis Among Families at Risk
Mar 12, 2018 07:00AM Alnylam Retains Global Rights to Lumasiran, an Investigational RNAi Therapeutic for the Treatment of Primary Hyperoxaluria Type 1 (PH1)
Mar 6, 2018 04:00PM Alnylam to Webcast Presentations at Upcoming March Investor Conferences
Feb 8, 2018 08:00AM Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results and Highlights Recent Period Activity
Feb 5, 2018 07:00AM Alnylam to Webcast Presentations at Upcoming February Investor Conferences
View More Recent Stories View Older Stories